Skip to main content
Premium Trial:

Request an Annual Quote

Two More to the RNAi Therapeutics List

Scientists at M.D. Anderson Cancer Center at the University of Texas have found that women with ovarian cancer who have low levels of critical RNAi proteins, Dicer and Drosha, die faster than those with high levels, says a story in The Wall Street Journal. Examining protein levels in 250 women with ovarian cancer, scientists led by Anil Sood found that women with high levels of Dicer and Drosha had a median survival of 11 years while women with low levels of one or both had a median survival of less than three years. Researchers hope to begin testing RNAi therapy on humans next year.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.